Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26

1. A method of treating a patient having a cancer that expresses CD26 comprising administering to said patient a pharmaceutical formulation comprising an anti-CD26 monoclonal antibody, whereby the anti-CD26 monoclonal antibody binds CD26 and arrests cell cycle, and wherein the cancer is a T-cell cancer, a B-cell cancer, a thyroid cancer, a lung adenocarcinoma, a prostate cancer, a stomach cancer, a testicular cancer, a uterine cancer, a brain cancer, a bone cancer, a rectal cancer, or a sarcoma.

2. The method of claim 1 , further comprising detecting cell cycle arrest.

3. The method according to claim 1 , wherein the monoclonal antibody is humanized.

4. The method of claim 1 , wherein the anti-CD26 antibody is an unconjugated antibody.

5. The method of claim 1 , wherein the anti-CD26 antibody is conjugated to a chemotherapeutic agent, a radionuclide, an imaging agent, a toxin, a biological agent, an enzyme inhibitor, or a second antibody.

6. The method of claim 5 , wherein the enzyme inhibitor is an adenosine deaminase inhibitor, or a dipeptidyl peptidase IV inhibitor.

7. The method of claim 1 , wherein the cancer is a T-cell cancer.

8. The method of claim 7 , wherein the T-cell cancer is a T-cell lymphoma or a T-cell leukemia.

9. The method of claim 1 , wherein the cancer is a B-cell cancer.

10. The method of claim 1 , further comprising treating the patient with a second agent, wherein the second agent is a therapeutic polypeptide, a nucleic acid encoding a therapeutic polypeptide, a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, a cytokine, a chemokine, an activating agent, or a biological response modifier.

11. The method of claim 10 , wherein the second agent is administered simultaneously with the anti-CD26 antibody.

12. The method of claim 10 , wherein the second agent is administered at a different time than the anti-CD26 antibody.

13. The method of claim 1 , wherein the cancer is characterized by tumor formation in said patient.

14. The method of claim 1 , wherein the administering is intravenous, intraarterial, intraperitoneal, intradermal, intratumoral, intramuscular, subcutaneous, intraarthricular, intrathecal, oral, dermal, nasal, buccal, rectal, or vaginal.

15. The method of claim 8 , wherein the T-cell cancer is a T-cell leukemia.

16. The method of claim 15 , wherein the T-cell leukemia is acute lymphoblastic leukemia, a T-cell chronic lymphocytic leukemia, a HTLV-related T-cell leukemia, or an adult T-cell leukemia.

17. The method of claim 8 , wherein the T-cell cancer is a T-cell lymphoma.

18. The method of claim 17 , wherein the T-cell lymphoma is a lymphoblastic lymphoma, a T-cell CD30+ anaplastic large cell lymphoma, a peripheral T-cell lymphoma, an angioimmunoblastic T-cell lymphoma, or an angiocentric T-cell lymphoma.

19. The method of claim 9 , wherein the B-cell cancer is a B-cell leukemia or a B-cell lymphoma.

20. The method of claim 19 , wherein the B-cell cancer is a B-cell leukemia.

21. The method of claim 20 , wherein the B-cell leukemia is B-cell chronic lymphocytic leukemia.

22. The method of claim 19 , wherein the B-cell cancer is a B-cell lymphoma.

23. The method of claim 1 , wherein the cancer is a thyroid cancer.

24. The method of claim 1 , wherein the cancer is a lung adenocarcinoma.

25. The method of claim 1 , wherein the cancer is a prostate cancer.

26. The method of claim 1 , wherein the cancer is a stomach cancer.

27. The method of claim 1 , wherein the cancer is a testicular cancer.

28. The method of claim 1 , wherein the cancer is a uterine cancer.

29. The method of claim 1 , wherein the cancer is a brain cancer.

30. The method of claim 1 , wherein the cancer is a bone cancer.

31. The method of claim 1 , wherein the cancer is a rectal cancer.

32. The method of claim 1 , wherein the cancer is a sarcoma.